Circulogene Theranostics Names James A. Posey III, M.D., as Chief Medical Advisor

Dr. James A. Posey, III

BIRMINGHAM, Ala., January 5, 2016 (BUSINESS WIRE)–Circulogene Theranostics the only biotechnology company able to enrich circulating cell-free DNA (cfDNA) from a single blood drop for patient-specific monitoring of cancer, has named medical oncologist James A. Posey III, M.D., as Chief Medical Advisor.

In his new role, Dr. Posey will help educate other oncologists about the efficacy and availability of Circulogene’s cfDNA liquid biopsy products and will be responsible for further validation of the company’s proprietary technology. Circulogene recently announced the commercial launch of its cfDNA tumor detection and monitoring products, which enable fast, accurate and personalized testing of 10 tumor types, including breast, lung and colon cancer.

“Dr. Posey is a powerful addition to our team as we extend the capabilities of our droplet-volumes-of blood testing methodology, providing physicians and their patients with a rapid, cost-effective cancer monitoring and treatment tool,” said Circulogene Theranostics CEO Mike Mullen.

Dr. Posey is a medical oncologist and Associate Professor of Medicine at the University of Alabama Birmingham and Senior Scientist at the UAB Comprehensive Cancer Center. He serves as Chair of the UAB Comprehensive Cancer Center GI Working Group and Chief GI Consultant for the Division of Hematology/Oncology at UAB Hospital.

“I am pleased and honored to provide critical direction and insight for this exciting venture,” said Posey. “I look forward to working with a highly skilled team focused on delivering non-invasive cancer tracking and monitoring, with the potential to improve quality of life and cancer treatment outcomes for millions of patients.”

Dr. Posey is a graduate of the Howard University College of Medicine in Washington, D.C. He completed his internship and internal medicine residency at Georgetown University Medical Center in Washington, D.C., and earned a fellowship in hematology/oncology at the Lombardi Cancer Center of Georgetown University Medical Center. Dr. Posey earned a second fellowship in developmental therapeutics, also from the Lombardi Cancer Center.

Certified by the American Board of Internal Medicine and the American Board of Medical Oncology, Dr. Posey has been in practice for 24 years. His research has been extensively published in numerous manuscripts and abstracts, and his current area of major interest is the activation and development of novel therapies for GI Cancers.

Circulogene is Clinical Laboratory Improvement Amendments (CLIA) certified and currently provides testing for the following cancers: breast, colorectal, lung, gastric, gastrointestinal stromal (GIST), hematological, melanoma, ovarian, pancreatic and thyroid. For more information, visit our website, connect with us on LinkedIn, email us at or call 855-614-7083. Clinicians interested in ordering the test may visit the Contact page on Circulogene’s website.

About Circulogene Theranostics

Headquartered in Birmingham, Ala., Circulogene Theranostics is an innovative molecular diagnostics company founded and operated by a team of experienced industry executives and skilled molecular diagnostics scientists. Applying its proprietary laboratory developed test for cfDNA liquid biopsies, Circulogene has developed the only droplet-volume, next-generation sequencing (NGS) method to provide full genomic load analysis, enabling more accurate data to help clinicians and their patients. For more information, visit or call 855-614-7083.


Media Contact
Armada Medical Marketing
Dan Snyders, 303-623-1190 ext. 230
Company Contact
Circulogene Theranostics
Scott Rezek, 205-278-1607